Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial
Tirzepatide injections can trigger localized skin reactions at the injection site in some patients, with studies showing that injection-site reactions occur in approximately 15-20% of users
GLP-1 receptor agonists now rank among the fastest-growing medication categories in America, with an estimated 1015 million Americans currently using them as of 2024
Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes
